Skip to main content

Current news

Tumor Profiler Center scientists describe strategy to target persister cancer cells

Therapeutic resistance in cancer treatment can be divided into primary resistance (lack of response to initial therapy due to preexisting genetic mutations) and acquired resistance (relapse despite initial response, caused by intratumor heterogeneity and other factors). While genetic alterations are known to contribute to acquired resistance, recent evidence suggests the involvement of non-genetic adaptive mechanisms.

Bernd Bodenmiller presents TPC at the Life Science Zurich Impact Conference DATA FOR HEALTH

@BodenmillerLab Precision Oncology keynote lecture
at the Life Science Zurich Impact Conference DATA FOR HEALTH 23 May 2023, at the Technopark Zurich.

We use cookies

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.